Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 3Withdrawn 1Completed 1

Sponsor Class

OTHER 3NIH 1FED 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Carcinoma, Transitional Cell 29Urinary Bladder Neoplasms 26Carcinoma, Renal Cell 22Carcinoma, Non-Small-Cell Lung 10Neoplasms 7Neoplasm Metastasis 7Squamous Cell Carcinoma of Head and Neck 6Ureteral Neoplasms 5Prostatic Neoplasms 5Ovarian Neoplasms 5Melanoma 5Carcinoma, Merkel Cell 5Urethral Neoplasms 4Triple Negative Breast Neoplasms 4Stomach Neoplasms 4Small Cell Lung Carcinoma 3Kidney Neoplasms 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Penile Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Lung Neoplasms 2Kidney Diseases 2Head and Neck Neoplasms 2Urothelial Cancer 1Urologic Neoplasms 1Turcot syndrome 1Testicular Neoplasms 1

Interventions

Gemcitabine 11pembrolizumab 8enfortumab vedotin 8Specimen Handling 8Cisplatin 8Magnetic Resonance Spectroscopy 6avelumab 5Carboplatin 5vinflunine 4Nivolumab 4atezolizumab 3Biopsy 3cabozantinib 2Standard of Care 2Ramucirumab 2Platinum 2Ipilimumab 2Immunoglobulin G 2Doxorubicin 2Docetaxel 2Disulfides 2CTLA-4 Antigen 2Bortezomib 21,2-diaminocyclohexaneplatinum II citrate 2vandetanib 1tocilizumab 1tamibarotene 1rucaparib 1relatlimab 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Ureteral Neoplasms × avelumab × Genitourinary × Clear all
NCT05092958 2026-05-13

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

National Cancer Institute (NCI)

Phase 3 Active not recruiting
654 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT04004442 2026-03-13

COAXIN

University of Oklahoma

Phase 1 Active not recruiting
19 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT04848519 2026-02-19

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

Emory University

Phase 2 Active not recruiting
6 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT05687721 2025-06-15

Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer

VA Office of Research and Development

Phase 1/2 Withdrawn
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT03617913 2023-01-06

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

Mayo Clinic

Phase 2 Completed
2 enrolled 8 charts
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡